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Background:Mutations in the subunits B, C, and D of succinate dehydrogenase (SDH) mitochondrial
complex II have been associated with the development of paragangliomas (PGL), gastrointestinal
stromal tumors, papillary thyroid and renal carcinoma (SDHB), and testicular seminoma (SDHD).
Aim: Our aim was to examine the possible causative link between SDHD inactivation and
somatotropinoma.
Patients and Methods: A 37-yr-old male presented with acromegaly and hypertension. Other
family members were found with PGL. Elevated plasma and urinary levels of catecholamines led
to the identification of multiple PGL in the proband in the neck, thorax, and abdomen. Adrenal-
ectomywas performed for bilateral pheochromocytomas (PHEO). A GH-secretingmacroadenoma
was also found and partially removed via transsphenoidal surgery (TTS). Genetic analysis revealed
a novel SDHDmutation (c.298_301delACTC), leading to a frame shift and a premature stop codon
at position 133 of the protein. Loss of heterozygosity for the SDHD genetic locus was shown in the
GH-secreting adenoma. Down-regulation of SDHD protein in the GH-secreting adenoma by im-
munoblotting and immunohistochemistry was found. A literature search identified other cases of
multiple PGL and/or PHEO in association with pituitary tumors.
Conclusion:We describe the first kindred with a germline SDHD pathogenic mutation, inherited
PGL, and acromegaly due to a GH-producing pituitary adenoma. SDHD loss of heterozygosity,
down-regulation of protein in the GH-secreting adenoma, and decreased SDH enzymatic activity
supports SDHD’s involvement in the pituitary tumor formation in this patient. Older cases of
multiple PGL and PHEO and pituitary tumors in the literature support a possible association be-
tween SDH defects and pituitary tumorigenesis. (J Clin Endocrinol Metab 97: E357–E366, 2012)
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Coexistence of pituitary adenomas and paraganglioma(PGL) or pheochromocytoma (PHEO) has not been
recognized as a syndrome. We have identified 25 cases of
acromegaly since 1964 copresenting with PHEO and one
report of extraadrenal PGL and acromegaly (1). Such
cases may represent a new multiple endocrine neoplasia
(MEN) rather than a fortuitous coexistence.
Mutations in the subunits B, C, and D and recently in
subunit A (SDHB, SDHC, SDHD and SDHA, respec-
tively) of the succinate dehydrogenase (SDH) mitochon-
drial complex II are known to be associated with the de-
velopment of PGL, PGL and gastrointestinal stromal
tumors (Carney-Stratakis syndrome), as well as with re-
nal, and papillary thyroid cancer, neuroblastoma, and ad-
renal medullary hyperplasia (2–12). A case of testicular
seminoma has also been reported in association with
SDHD mutation (13).
In the present report, we had the opportunity to study
a unique family with multiple members affected by PGL
caused by a novel SDHD-inactivating mutation. The pro-
band presented with acromegaly, PHEO and PGL. Ge-
netic studies in his GH-secreting adenoma showed loss of
SDHD expression consistent with a possible tumor sup-
pression function in the pituitary tumor of this patient.
Subjects and Methods
Clinical studies and tissue samples
The institutional review boards of the participating institu-
tions have approved all studies. Blood and tissue samples were
collected fromthepatient and the familymembers after informed
consent was obtained. Tissueswere collected at surgery and pro-
cessed for routine histopathology and immunohistochemistry
after formalin fixation and paraffin embedding.
Hormonal assays
Plasma and urinary catecholamines and metanephrines were
measured using standard assays, as described previously, at the
National Institutes ofHealthWarrenMagnusonClinical Center
and Mayo Clinical Medical Laboratories.
DNA preparation and sequencing studies
DNAwas extracted fromperipheral blood leukocytes, frozen
tissue samples, or cell lines according to manufacturer protocols
(QIAGEN, Valencia, CA). Mutation analysis for exons and the
surrounding intron boundaries was performed for SDHB,
SDHC, SDHD,MEN1, AIP, and CDKN1B genes; the four ex-
ons of SDHD, eight exons of SDHB, six exons of SDHC, six
exons of AIP, and two exons of CDKN1B were amplified and
sequenced by PCR-based bidirectional Sanger sequencing. The
primers used for SDHB, SDHC, SDHD, andMEN1 have been
described elsewhere (14, 15). The primers forAIP andCDKN1B
mutation analysis are described in Supplemental Table 1 (pub-
lished on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org). All amplified samples were ex-
amined by agarose gel electrophoresis to confirm successful am-
plification of each exon. Direct sequencing of the purified frag-
ments was then done using the Genetic Sequencer ABI3100
AppliedBiosystems (FosterCity,CA) apparatus. Sequenceswere
analyzed using Vector NTI 10 software (Invitrogen, Carlsbad,
CA).
Immunohistochemistry (IHC)
All IHCwas performed in collaborationwithHistoserve, Inc.
(Germantown, MD) using standard procedures. Slides from the
patient’s pituitary tumor and PHEO were compared with those
froma pituitary adenoma froma patient negative for any known
mutations, from tissue from a normal pituitary gland and from
sporadic PHEO. The following primary antibodies were used:
SDHD, sc-67195, rabbit polyclonal IgG (Santa Cruz Biotech-
nology, SantaCruz,CA); SDHB,HPA002868, rabbit polyclonal
IgG (Sigma-Aldrich Inc., St. Louis, MO); and GH receptor
(GHR) [N3C2], internal, GTX101192, rabbit polyclonal IgG
(Gene Tex, Irvine, CA).
Quantitative real-time PCR
SDHD loss of heterozygosity (LOH) was analyzed by quan-
titative real-time PCR using SYBR Green in an ABI 7700 Se-
quenceDetection System (AppliedBiosystems). The PCRcycling
conditions were as follows: 2 min at 95 C, 40 cycles of 95 C for
15 sec and 60C for 30 sec, and a final step at 72C for 30 sec. The
primer sequences for wild-type (WT) and mutant SDHD alleles
are available in Supplemental Table 1. A cycle threshold (CT)
value in the linear range of amplification was selected for each
sample in triplicate. SDHD dosage was determined using the
2CT method. The normalized value (CT) for the WT and
mutant SDHD allele in the tumor sample was then compared
with the CT of both alleles in the peripheral DNA to produce
a fold change ratio (normal dosage  1).
Immunoblotting
Western blot analysiswas performed following standard pro-
cedures. Briefly, cells were lysed by homogenization in 20 mM
Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 1% Nonidet
P-40, 0.5% sodium deoxycholate, and protease inhibitor cock-
tail I (EMD Biosciences, La Jolla, CA) with subsequent centrif-
ugation at 10,000 rpm for 10 min at 4 C. Equal amounts of
protein lysate were subjected to SDS-PAGE, transferred to ni-
trocellulose membranes, and probed with antibodies. The fol-
lowing antibodies were used for immunoblotting: SDHD,
H00006392-M04, mouse monoclonal IgG (Novus Biologicals,
Littleton, CO); SDHB, HPA002868, rabbit polyclonal IgG (Sig-
ma-Aldrich Inc., St. Louis, MO), GHR [N3C2], internal,
GTX101192, rabbit polyclonal IgG (Gene Tex); and hypoxia-
inducible factor-1 (HIF-1), NB100-479, rabbit polyclonal
IgG (Novus Biologicals).
Enzyme assay
For enzymatic assays, tissue homogenates were prepared us-
ing amechanically driven (500 rpm/six strokes) Potter-Elvejhem
homogenizer (Vineland, NJ) in 500 l of an ice-cold solution
consisting of 0.25 M sucrose, 20 mM Tris-HCl (pH 7.2), 2 mM
EGTA, 40 mM KCl, and 1 mg/ml BSA. Activities of respiratory
chain complexes were measured by spectrophotometer using a
Cary 50 UV-visible spectrophotometer (Varian Inc., Les Ulis,
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France) as previously described (16, 17).All chemicalswere from
Sigma-Aldrich (St. Quentin, Falavier, France).
Statistical analysis
All statistical analyses were performed with the SPSS version
16.0 (SPSS Inc., Chicago, IL). Continuous data are expressed as
mean  SE. A two-sample t test was used for statistical analysis
of gene dosage betweenWTandmutant alleles. AP value 0.05
was considered significant.
Results
Clinical course and investigation
The proband was a 41-yr-old man who was first eval-
uated at 37 yr for a pituitary mass detected on brain mag-
netic resonance imaging (MRI). He had a 3-yr history of
hypertension controlled with calcium channel blockers,
diuretics, and angiotensin II receptor inhibitors. The fam-
ily history was remarkable for hypertension and type 2
diabetes in the patient’s mother, whereas the patient’s fa-
ther passed away from lung cancer at the age of 65 (Fig.
1A). The patient was clearly acromegalic upon presenta-
tion. Hormonal evaluation revealed GH of 10.70 ng/ml
(normal is 5 ng/ml) and IGF-I of 492 ng/ml (normal is
109–284ng/ml).Calcitonin andPTHwerenormal; serum
prolactin (PRL) was mildly increased at 25.5 ng/ml (nor-
mal is18); testosterone was decreased at 78 ng/dl (nor-
mal is 200–980 ng/dl). The patient had impaired fasting
glucose according to standard criteria (18) and mild dys-
lipidemia with cholesterol at 225 mg/dl (normal is 130–
200 mg/dl), high-density lipoprotein at 77 mg/dl (normal
is 55 mg/dl), and low-density lipoprotein at 135 mg/dl
(normal is165mg/dl). A pituitaryMRI showed a 3.5-
4.3-  3-cm pituitary mass. The mass had invaded the
right cavernous sinus and extended into the suprasellar
region compressing the optic chiasm (Fig. 1B1).
The patient was placed on long-acting somatostatin
analog (LASMSA) and showed a partial clinical and lab-
oratory response (Table 1). The patient was scheduled for
FIG. 1. A, Pedigree of the studied family. The arrow indicates the proband. B1, Coronal MRI scan of the pituitary gland without contrast. There is
a large pituitary adenoma extending into the suprasellar region and compressing the optic chiasm (long arrows). There is evidence of invasion of
both cavernous sinuses. The adenoma has also eroded the floor of the sella turcica and occupied the sphenoid sinus (short arrow). B2, Axial post-
contrast computed tomography scan of the neck. Large enhancing tumors are identified in the soft tissues of the neck bilaterally (arrows). They are
located at the bifurcation of the common carotid arteries between the proximal end of the internal and external carotids. The location of these
tumors and the intense enhancement are typical for carotid body tumors. B3, Axial inversion recovery MRI scan of the upper abdomen with fat
suppression. Tumor masses are identified in both adrenal glands with the right being larger than the left. Both tumors demonstrate high signal
intensity with this technique (arrows). They are also intensely enhanced on the post-contrast scans (not shown). Histological examination of both
tumors after complete surgical resection revealed PHEO.
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transsphenoidal surgery (TSS) after a year of treatment led
to no improvements. Five tumors with characteristics typ-
ical for PGL were detected by computed tomography and
MRI of the neck: two originating from the carotid bodies,
two located in the jugular fossae, and one in the soft tissue
at the carotid bifurcation (Fig. 1B2) and the base of the
skull.Therewerealso threemasses in the thorax;oneat the
paraspinal region (fifth thoracic vertebra), one at the left
pulmonary hilum, and the third at the epicardium. Two
additional tumors were found in the retroperitoneum be-
low the diaphragm and one in each adrenal gland (Fig.
1B3). [18F]Fluorodopapositron emission tomography im-
agingwas also performed that showed avid concentration
of the radionuclide in each of these tumors.
Plasma norepinephrine was 847 pg/ml (normal is 120–
350 pg/ml), and urine normetanephrine was 3506 g/24
h (normal is 500 g/24 h). Plasma dopamine was also
elevated at 153 ng/liter (normal is 30–120 ng/liter) as well
as chromogranin A at 1087 ng/ml (normal is98 ng/ml).
Initially, the patient underwent bilateral adrenalectomy,
and the diagnosis of PHEO was confirmed by histology.
The pheochromocytoma of the adrenal gland scaled score
(PASS) was 8, and Ki67 was 1%. Ten months later at the
National Institutes of Health, just before TSS, plasma
normetanephrine was 2396 pg/ml (normal is 112 pg/
ml), 24-h urine normetanephrine was 2220 g/24 h (nor-
mal is 419 g/24 h), norepinephrine was 361 g/24 h
(normal is 80 g/24 h), metanephrine was less than 29
g/24 h, and IGF-I was 774 ng/ml (normal is284 g/24
h) (Table 1). The GHRH serum level was within the nor-
mal range at 9 pg/ml (normal is 5–18 pg/ml). The pituitary
adenoma was partially resected. This somatotropinoma
also stained positive for PRL; it was P53 negative with a
low proliferation index. He was placed on LASMSA and
3 months after TSS, the levels of IGF-1 and GHwere nor-
malized (Table 1). During his follow-up and while on
LASMSA, a significant decrease in plasma and urine
normetanephrine was detected (Table 1 and Fig. 2A). The
size of the PGL was stabilized.
Genetic and expression studies
The possibility of a hereditary syndrome was strongly
suggested; family history revealed the case of a paternal
uncle who had been operated 39 yr earlier for bilateral
neck masses (Fig. 1A). Genetic analysis of the SDHB,
SDHC, and SDHD genes revealed a novel SDHD exon 3
mutation (c.298_301delACTC), resulting in a frame shift
and premature stop at codon 133. The samemutationwas
detected in the patient’s affected relatives. The patientwas
also tested for genesMEN-1, AIP, and CDKN1B: he had
no MEN1 mutations, whereas one common polymor-
phism was detected in CDKN1B (c.326 T3G p.V109G)
and another one in AIP (c.682 C3A, p.Q228K).
We then looked for SDHDLOH in tumor cells. Indeed,
the SDHDWT allele was significantly reduced in the pi-
tuitary tumor in relation to the patient’s peripheral blood
(SDHD WT allele copy number at 0.3  0.04 vs. 1.0 
0.01; P 0.0001) (Fig. 3A). In addition, Western blot of
extracts from the patient’s pituitary tumor showed almost
no expression of SDHD (Fig. 3B).
The 15-kDa band corresponding to the SDHD protein
was present in normal pituitary as well as in extracts from
pituitary tumor cells from another patient with acromeg-
aly who did not have SDHx mutations (Fig. 3B). Consis-
tent with the LOH and Western blot studies, IHC for
SDHD was negative in the patient’s pituitary tumor (Fig.
4.1) compared with that in normal pituitary cells (Fig.
4.2). Staining for SDHB showed diffuse but patchy stain-
ing in some areas of the tumor (Fig. 4.3); in other areas,
SDHB staining was negative (Fig. 4.4). Normal pituitary
showed also diffuse SDHB staining (Fig. 4.5) unlike what
has been reported (19).We then looked for the expression
TABLE 1. Clinical and biochemical response to treatment over time
Baseline
3 months
after
LASMSA Rx
6 months
after
LASMSA Rx
12 months
after
LASMSA Rx
24 months
after LASMSA
Rx (before
TSS)
3 months
after
TSS
14 months
after
TSS
26 months
after
TSS
GH (ng/ml) 10.7 12.4 8.24 15.9 6.2 1.53 0.9
IGF-I (ng/ml) 492 439 456 530 774 126 169 194
Optic fields Left eye
nasal
scotoma
Normal Normal Normal Normal Normal Normal Normal
Urine
normetanephrine
(g/24 h)
3506 2220 727 986
Plasma
normetanephrine
(pg/ml)
2396 465 454
Rx, Treatment.
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of SDHB in the patient’s pituitary tumor cells by Western
blot. The 34-kDa band corresponding to the SDHB pro-
tein was weaker compared with the ones detected in ex-
tracts from normal pituitary as well as the GH-secreting
adenoma without SDHx mutation (Fig. 3C). Staining for
SDHB and SDHD in patient’s PHEO was negative (Fig.
4.6 and4.7).HIF-1 expressionwas found tobe increased
in our patient’s tumor extracts compared with normal pi-
tuitary (Fig. 3C).
We also looked for any expression of GHR in extracts
from PHEO from patients with SDHB and SDHDmuta-
tions and in paraffin-embedded tissue derived from our
patient’s resected PHEOand from twoother patientswith
sporadic PHEO.Western blot of extracts fromPHEOhar-
boring SDHx mutations showed a strong expression of
GHR: the 72-kDa band corresponding to the GHR pro-
tein was present in both samples (Fig. 2B). IHC for GHR
showed positive diffuse staining in our patient’s sample
(Fig. 2C1). Staining was weaker in the two samples from
sporadic PHEO without any known mutations (Fig. 2C2
and -3).
Enzymatic activity
To assess the effect of the identified mutation on respi-
ratory chain function, we performed enzymatic assays on
homogenates prepared from the pituitary tumor tissue or
control samples. The assay involved the measurement of
theoxidationof added reduced cytochromec (cytochrome
oxidase activity) and subsequent reduction of added ox-
idized cytochrome triggered by succinate (complex IIIII
activity) or decylubiquinone (complex III activity). Upon
addition of oxidized cytochrome c, before addition of any
reducing substrate, a significant reduction of cytochrome
c tookplace in the tumorhomogenate, suggesting thepres-
ence of a significant amount of an endogenous reducing
substance. Upon the subsequent addition of succinate,
complex II substrate, increased rates of cytochrome c re-
duction in both set-ups were noted that were essentially
sensitive to malonate, a specific inhibitor of complex II
(Fig. 5).Wenext performed an isolated complex II activity
assay using decylubiquinone (in the presence of dichloro-
phenol indophenol) as an electron acceptor. A 15–20%
decrease in activity was measured in tumor tissue com-
pared with control (P  0.08).
FIG. 2. A, Catecholamine levels over time; B, Western blot of extracts from PHEO harboring SDHx mutations showed a strong expression of GHR
in both samples; C, staining for GHR was positive in our patient’s resected PHEO (C1) and weak (C2) to almost negative (C3) in two sporadic
adenomas. Original magnification, 20.
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Discussion
We describe for the first time the association of a novel
germline SDHD pathogenic mutation with inherited PGL
and a GH-producing pituitary adenoma. SDH partici-
pates in the electron transfer of the respiratory chain and
in the conversion of succinate to fumarate as the complex
II in oxidative phosphorylation as well as in the citric acid
cycle (4, 20); its function and expression in the pituitary
gland is as important as in all other tissues. It has been
shown that SDH subunits act as tumor suppressor genes
following the Knudson two-hit hypothesis (20, 21). The
precise pathway leading from SDH mutation to tumori-
genesis is not yet fully elucidated, but one of the mecha-
nisms proposed is through accumulation of HIF-1 and
-2 (22–25). SDH-inactivatingmutations create apseudo-
hypoxia state that is characterized by succinate and reac-
tive oxygen species accumulation, resulting in increased
HIF levels that in turn activate oncogenesis (20, 22–27).
Indeed, HIF1 immunoblotting in our patient’s tumor
showed increased expression comparedwith aGH-secret-
ing adenoma without SDH defects and with normal pitu-
itary (Fig. 3C). Impairedoxidative phosphorylation forces
the tumor cell to create ATP glycolytically even during
normoxia, the so-called Warburg effect (22).
The structure ofmitochondrial complex II or succinate-
ubiquinone oxidoreductase (mitochondrial SQR) con-
tains four proteins: flavin adenine dinucleotide-binding
protein or flavoprotein (Fp or subunit A), iron-sulfur pro-
tein (Ip or subunit B), and twomembrane-anchor proteins
(CybL or subunit C andCybS or subunit D)with a total of
six transmembrane helices. Subunits A and B form the
soluble catalytic heterodimer, whereas subunits C and D
FIG. 3. Panel A, Relative expression of WT and mutant allele in the tumor and peripheral blood. Amplification of the SDHD WT allele was
significantly reduced in the pituitary tumor in relation to the patient’s peripheral blood (SDHD WT allele copy number, 0.3  0.04 vs. 1.0 
0.01; P  0.0001). Panel B, Western blot of SDHD expression in patient’s tumor (P) and in normal pituitary (NP) as well as in extracts from
pituitary tumor cells from a patient with acromegaly without SDHx mutations (C). Panel C, Western blot of SDHB expression in patient’s
pituitary tumor (P) was decreased, whereas HIF1 was significantly increased, compared with normal pituitary (NP) and with a patient with
acromegaly without SDHx (C).
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form the hydrophobic membrane anchor (28). Subunit D
has four helices: helix 1S (D36–D62), helix 2S (D66–
D92), helix 3S (D95–D123), and helix 4S (D126–D136)
(27). There are at least two ubiquinone-binding sites in
eukaryotic mitochondrial succinate-ubiquinone oxi-
doreductase. One site (Qp) is on the matrix side, and the
second (Qd) is near the intermembrane-space side. The
latter is formed by the loop between the helix 1S and helix
2S and helix 4S and the C terminus of CybL (29). The
mutation reported in the present case is a 4-bp deletion
(ACTC) at position c.298_301, which, based on the de-
scribed structure, would result in missing both helices 3S
and 4S of subunit D. This most probably would prevent
ubiquinone from binding to the Qd site, disrupting the
transportation of the high-energy electrons through the
respiratory chain.
Since the discovery of the SDHx genes (30) and its re-
lation to familial PGL/PHEO, other forms of tumors as-
sociated with inactivating SDH subunit mutations have
been described in recent years in gastrointestinal stromal
tumors and in Carney-Stratakis syndrome (2, 3), in renal
cancer (10, 11), in patients with PTEN-negative Cowden
and Cowden-like syndrome (7), in thyroid cancer (10),
and in patients with adrenal medullary hyperplasia (12).
Wewereable to identify25casesofpituitaryadenomaand
PHEO in the literature (1). The pituitary tumors have in-
cludedGH-,PRL-, andACTH-secretingandnonfunction-
ing adenomas.
Given these data, we examined whether the pituitary
tumor in our kindredwas due to the SDHDmutation. The
patient did not have any mutations in MEN1, AIP, and
CDKN1B genes. Because SDHD acts as tumor suppressor
gene, we examined whether LOH was present in the pa-
tient’s pituitary tumor. Indeed, themutated allele was pri-
marily expressed in the pituitary tumor, whereas both al-
leles were equally expressed in the peripheral blood. In
fact, the detection of any expression of the normal allele in
the pituitary tumor was most likely due to contamination
by normal cells as often is the case in tissue lysates (31).
SDHDexpressionbyWesternblot and IHCwasdecreased
in the patient’s pituitary tumor, compared with a GH-
secreting adenoma negative for SDHDmutation andwith
normal pituitary. SDHB expression was also significantly
reduced by immunoblotting (Fig. 3C). SDHB stainingwas
positive for parts of the pituitary tumor (Fig. 4.3),whereas
other parts of the tumor were completely negative (Fig.
FIG. 4. IHC showed loss of expression of SDHD protein (4.1) compared with normal pituitary (4.2). SDHB staining was positive for part of the
tumor (4.3) whereas in other parts was totally negative (4.4). Normal pituitary showed strong diffuse SDHB staining (4.5). Patient’s PHEO was
stained negative for both SDHB and SDHD (4.6 and 4.7) Original magnification, 20 (4.1, 4.2, 4.6, and 4.7) and 100 (4.3–4.5).
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4.4). The patient’s PHEO was negative for SDHB and
SDHD (Fig. 4.6 and 4.7), which is in accordance with van
Nederveen et al. (19)who have shown that SDHB staining
is absent in all tumors harboring an SDHx mutation.
However, in their paper, Gill et al. (32) showed that com-
pletely absent staining ismore commonly found in tumors
withSDHBmutation,whereasweakdiffuse stainingoften
occurs in those with SDHD mutation. Our findings in
pituitary tumor agree with Gill et al. (32); the SDHD-
deficient pituitary tumor had some staining for SDHB un-
like what would be expected from an SDHB-mutant le-
sion. In addition, SDHB staining was patchy; some areas
had relatively strong staining for SDHB, others less, and
others were completely negative. It is unclear what this
patchy staining is from; the genetic data and allelic heter-
ogeneity supported a possible polyclonal origin or sub-
stantial contamination with normal cells. Unless one had
access to cells obtained by microdissection from well-de-
finedareasof the tumor, theabove conundrumwill remain
unanswered.
We also measured the SDH enzy-
matic activity in a tissue sample from
normal pituitary aswell in a tissue sam-
ple from our patient’s pituitary ade-
noma. It is interesting that initially,
whenwe added oxidized cytochrome c,
a significant reduction of cytochrome c
took place in the tumor homogenate,
suggesting the presence of a significant
amount of one or more endogenous re-
ducing substances (Fig. 5). This could
represent either reducing acids result-
ing from SDH impairment or oxida-
tively modified compounds resulting
from unstable reactive oxygen species,
possibly produced as a result of SDHx
mutations (23).Whenwemeasured the
activity of SHD alone, a 15–20% re-
ductionwas found in tumor tissue com-
paredwith control (P0.08).Onepos-
sible explanation for the fact that the
SDH activity was not completely abol-
ished in the tumor may be that the ho-
mogenate contained normal cells,
which compensated for the reduced ac-
tivity of the tumor cells. Unfortunately,
we did not have enough tumor cell lines
with homogeneous cell populations to
answer these questions properly.
Studies in family members (Fig. 1)
did not reveal any pituitary tumors.
Whether carriers develop the tumor
depends on many factors (33); in ad-
dition, the age-related penetrance of SDHD-linked PGL
is 54% by the age of 40 yr and 68% by the age of 60 yr,
reaching a maximum of 87% by the age of 70 yr (34).
Review of the other cases reported in the literature did
not reveal the presence of PGL and pituitary adenomas
in other family members. Genetic analysis was not per-
formed in most cases, except for RET (35, 36). It is also
possible that some of these cases are due to GHRH-
secreting neuroendocrine tumors (37, 38).
Another interesting finding in our index case was a
noticeable decrease (almost three times) of plasma and
urinary norepinephrine and normetanephrine levels 14
and 26 months after TSS, which was greater than the one
noted 10 months after adrenalectomy (Fig. 2A). No pro-
gression in the size of the multiple PGL was noticed. One
possibility is that LASMSAhad an effect on catecholamine
release; however, thedeclinewasnot seenbeforeTSSdespite
the patient being on LASMSA for 10 months, and it was
sustained after TSS evenwhen thepatient stayedoffLASMSA
FIG. 5. Respiratory chain activity in control (Ctrl) and tumor (Tum) tissues samples. A and B,
Cytochrome c oxidase (complex IV) activity is first measured, triggering the oxidation of
the added reduced cytochrome c (Cyt c). After addition of oxidized cytochrome c and the
subsequent inhibition of complex IV by cyanide (KCN) and complex I by rotenone (Rot), the
activity of the succinate cytochrome c reductase (complex IIIII) is initiated by the addition of
succinate and specifically inhibited by malonate. The final addition of glycerol-3 phosphate
(G-3P) permits estimation of the activity of the G-3P cytochrome c reductase (G-3P
dehydrogenasecomplex III). Notice that in the tumor sample (B) compared with control (A) a
spectacular reduction of the oxidized cytochrome c added after the measurement of the
cytochrome c oxidase took place, indicating the huge accumulation of reducing compounds
in the tumor tissue (A). C and D, Measurement of the malonate-sensitive succinate quinone
reductase (complex II; succinate dehydrogenase) activity in control (C) and tumor (D) samples.
Assay medium was initially supplemented with 80 M dichlorophenol indophenol and 0.3 mM
KCN; the reaction is initiated by the addition of succinate and decylubiquinone (DCQ) and
inhibited by the addition of malonate. Numbers along the traces are nanomoles per minute
per milligram protein. Experimental conditions are as described in Materials and Methods.
E364 Xekouki et al. SDHD and Acromegaly J Clin Endocrinol Metab, March 2012, 97(3):E357–E366
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 21 February 2014. at 03:08 For personal use only. No other uses without permission. . All rights reserved.
for brief periods of time. Thus, we assumed that normal-
ization of GH levels after TSS contributed significantly to
such biochemical changes. We showed that GHRwas ex-
pressed in two PHEO samples from other patients har-
boring each an SDHB and an SDHD mutation, respec-
tively, as well as in the PHEO from our patient. As far as
we know, this is the first time that the expression of GHR
is shown in PHEO. There are only reports for the differ-
ential expression of ghrelin and GHRH receptors in var-
ious adrenal tumors (PHEO included) (39, 40). Clearly,
larger andmore detailed studies are needed to address and
confirm this very interesting observation and the role of
GHR in SDHx-mutant tumors.
In conclusion, we have identified a novel SDHD mu-
tation in a patient with multiple functioning PGL and a
pituitary adenoma. Whether the SDH genes are indeed
predisposing genes for pituitary tumors requires addi-
tional studies; this report only suggests that a careful fam-
ily history regarding pituitary tumors should be consid-
ered in patients with multiple PGL or with any germline
genetic defects of the SDH genes.
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